Clinical trialNCT03233347Active, not recruitingPhase 2Interventional

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

SponsorAcademic and Community Cancer Research UnitedEnrollment83Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage II Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin Lymphoma+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Steven I Park
Academic and Community Cancer Research United
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Carolinas Medical Center/levine Cancer Institute
Charlotte, North Carolina, United States
University of Pennsylvania/abramson Cancer Center
Philadelphia, Pennsylvania, United States
Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
M D Anderson Cancer Center
Houston, Texas, United States
University of Washington Medical Center - Montlake
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Brentuximab vedotin →DacarbazineDoxorubicin →Nivolumab →Vinblastine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Oct 2017
Primary completion: 1 Jul 2025
Completion: 8 Jul 2027
Last update posted: 15 Sept 2026
Registered enrollment: 83
Registry id: NCT03233347

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.